TransThera-B (02617): First patient dosed in China Phase II clinical trial of tinengotinib combined with novel endocrine therapy for previously treated progressive metastatic castration-resistant prostate cancer

Zhito Finance APP News, TransThera-B (02617) announced that the first patient has recently been dosed in the China Phase II clinical trial of the Company's core product tinengotinib (Jienntai, Tinengotinib, TT-00420) in combination with novel hormonal therapy (NHT) for previously treated, progressive metastatic castration-resistant prostate cancer (mCRPC).